Cellectis CLLS
NASDAQ CLLS
$3.24 -0.08 (-2.41%)
At close: Sep 4, 2026 · 4:00 PM EDT

Cellectis (CLLS) Net Margin (2015 - 2026)

Cellectis (CLLS) posted quarterly Net Margin of 0.0% for Q1 2026, little changed year-over-year from 0.0% in Q1 2025, and down 52.39% quarter-over-quarter from 0.0% in Q4 2025.

Analysis

Cellectis (CLLS) Net Margin (2015 - 2026) Analysis & Trends

Cellectis' Net Margin history runs 12 years deep, the most recent figure standing at 0.0% for Q1 2026.

  • In Q1 2026, Net Margin changed 0.0% year-over-year to 0.0%; the TTM figure through Mar 2026 stood at 32.88% (up 4374.0% YoY), while the FY2025 annual figure was 0.0%, up 7469.0% from the prior year.
  • Net Margin for Q1 2026 stood at 0.0%, down from 0.0% in the prior quarter.
  • The five-year high for Net Margin was 124.62% in Q1 2024, with the low at 21635.97% in Q1 2023.
  • The 5-year median for Net Margin is 167.34% (2022), against an average of 3541.98%.
  • The sharpest annual moves came in 2023 and 2024: Net Margin slumped 1971939 bps in 2023, then soared 2176060 bps in 2024.
  • Cellectis' Net Margin stood at 167.34% in 2022, then sank by 186 bps to 479.25% in 2023, then soared by 106 bps to 28.99% in 2024, then plunged by 100 bps to 0.0% in 2025, then plunged by 52 bps to 0.0% in 2026.
  • Business Quant data shows CLLS's Net Margin at 0.0% in Q1 2026, 0.0% in Q4 2025, and 1.67% in Q3 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Margin (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 32.99%
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 30.23%
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 31.16%
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -539.31%
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 13.90%
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 12.74%
8 Royalty Pharma 28.45 Bn 27.61 Bn - 12.09%
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn -3.12%
10 Cellectis 321.90 Mn 155.05 Mn - -301.13%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -301.13%
Mar 31, 2026 -311.58%
Dec 31, 2025 0.00%
Sep 30, 2025 1.67%
Jun 30, 2025 -141.92%
Mar 31, 2025 -168.93%
Dec 31, 2024 46.57%
Sep 30, 2024 -142.32%
Jun 30, 2024 -313.48%
Mar 31, 2024 124.62%
Dec 31, 2023 -14,768.55%
Sep 30, 2023 -11,278.71%
Jun 30, 2023 -6,576.97%
Mar 31, 2023 -21,635.97%
Dec 31, 2022 -167.34%
Sep 30, 2022 -16,266.86%
Jun 30, 2022 -1,449.58%
Mar 31, 2022 -1,916.58%
Dec 31, 2021 -243.59%
Sep 30, 2021 -450.11%